C O M M U N I C A T I O N S
Scheme 2a
Scheme 3a
a (a) TIPS-Cl, imid, DMF, rt, 16 h; (b) DiBAl-H, CH2Cl2, -10 °C, 50
min, 78% (2 steps); (c) TMS-acetylene, Et2Zn, toluene, reflux, 1 h, then
(S)-Binol, Ti(Oi-Pr)4, then 13, rt, 20 h, 66%; (d) benzoyl chloride, DMAP,
pyridine, rt, 4 h, 100%; (e) HF/H2O, CH3CN, rt, 12 h, 93%; (f) Dimethyl
sulfate, n-Bu4NHSO4, NaOH, toluene/H2O, 0 °C to rt, 3.5 h, 95%; (g) HF,
CH3CN, rt, 24 h then NaOCl, NaClO2, TEMPO, CH3CN, phosphate buffer
(pH 6.7), 45 °C, 18 h, 99%; (h) SerOMe‚HCl, EDC, HOBT, NMM, CH2Cl2,
0 °C to rt, 16 h, 55%; (i) DAST, CH2Cl2, -78 °C, 1 h then K2CO3, -78
°C to rt, 40 min; (j) DBU, BrCCl3, CH2Cl2, 0 °C to 4 °C, 20 h; (k) NBS,
AgNO3, acetone, rt, 1 h, 54%; (l) n-Bu3SnH, PdCl2(PPh3)2, THF, -78 °C
to rt, 3 h, then I2, 0 °C, 45 min, 92%; (m) LiOH, H2O, THF, rt, 12 h, 97%.
a (a) 3, PdCl2(PPh3)2, CuI, Et3N, CH3CN, -20 °C to rt, 75 min, 94%;
(b) 19, DCC, DMAP, CH2Cl2, 0 °C to rt, 14 h, 80%; (c) 3, PdCl2(PPh3)2,
CuI, Et3N, CH3CN, -20 °C to rt, 75 min, 94%; (d) LiOH, H2O, THF, rt,
13.5 h, 98%; (e) 2,4,6-trichlorobenzoyl chloride, Et3N, THF, rt, 2 h then
DMAP, toluene, rt, 16 h, 79%; (f) DDQ, phosphate buffer, CH2Cl2, rt, 15
min, 61%; (g) H2, Lindlar catalyst, quinoline, EtOAc, rt, 1 h, 57%.
Silyl ether protection of hydroxy nitrile 12 followed by reduction
with DiBAl-H afforded aldehyde 13 in 78% yield (Scheme 2). The
transformation of 13 to the propargylic alcohol 6 utilized the
methodology of Pu and co-workers.6 The alkynyl zinc reagent
derived from TMS-acetylene and diethylzinc was added to 13 in
the presence of a catalyst formed in situ from Ti(i-OPr)4 and (S)-
Binol. For the determination of the %ee of this transformation, 6
was converted to benzoate 14 and analyzed by chiral HPLC.
Dimethyl sulfate under phase-transfer conditions converted 6 to
the methyl ether 15 in 95% yield with concomitant loss of the
trimethylsilyl group. Carboxylic acid 1614 was obtained by removal
of the TIPS group with aqueous HF in acetonitrile, neutralization
with aqueous NaOH, and oxidation using the Merck protocol.15
Cyclodehydration of the hydroxy amide obtained from 16 and serine
methyl ester was accomplished using diethylaminosulfurtrifluoride
(DAST) followed by BrCCl3 and DBU16 to afford oxazoles 17 and
18. The alkynyl bromide 17 was an unexpected outcome, but
allowed for an efficient conversion to the required vinyl iodide 4
in 92% yield by Pd-catalyzed hydrostannylation.17 Finally, 4 was
converted to the carboxylic acid segment 19 in 97% yield by
saponification with aqueous LiOH in THF.
Both segments 3 and 4 were going to be utilized twice in the
convergent construction of disorazole C1. The chain extension
sequence to the seco-macrodiolide was initiated by Sonogashira
cross-coupling of 3 and 4 to afford the protected monomer 20 in
94% yield (Scheme 3). Acylation of 20 with an excess of 19 led to
21 in 80% yield. A second Sonogashira coupling between 21 and
3 afforded seco-disorazole C1 in 94% yield. Selective mono-
saponification of methyl ester 22 was followed by a Yamaguchi
lactonization18 to give macrocycle 2 in 79% yield. While thus far
the segment assembly had benefited from oustanding yields and
efficiency, the next steps required extensive optimization to avoid
decomposition of the oligo-enyne scaffold of the natural product.
The PMB ethers were removed with DDQ under buffered conditions
to afford the diol in 61% yield. Finally, double alkyne reduction
with Lindlar catalyst in the presence of excess quinoline afforded
1 in 57% yield after HPLC purification.19
complished in 20 steps and 1.5% yield for the longest linear
sequence. Notable features include the concise formation of iodo-
alkene 4 and the selective functional group manipulations including
the conversion of PMB-protected hexaene-diyne 2 to the highly
labile octaene natural product. This total synthesis also establishes
the correct relative and absolute configuration of the disorazoles.
Acknowledgment. This work was supported by a grant from
the National Institutes of Health (GM-55433).
Supporting Information Available: Experimental procedures and
1
spectral data for all new compounds, including copies of H and 13C
NMR spectra. This material is available free of charge via the Internet
References
(1) Jansen, R.; Irschik, H.; Reichenbach, H.; Wray, V.; Ho¨fle. G. Liebigs
Ann. Chem. 1994, 759.
(2) Reichenbach, H. J. Ind. Microbiol. Biotech. 2001, 27, 149.
(3) Irschik, H.; Jansen, R.; Gerth, K.; Ho¨fle, G.; Reichenbach, H. J. Antibiot.
1995, 48, 31.
(4) Synthetic studies: (a) Hillier, M. C.; Price, A. T.; Meyers, A. I. J. Org.
Chem. 2001, 66, 6037. (b) Hartung, I. V.; Eggert, U.; Haustedt, L. O.;
Niess, B.; Schaefer, P. M.; Hoffmann, H. M. R. Synthesis 2003, 1844.
(c) Haustedt, L. O.; Panicker, S. B.; Kleinert, M.; Hartung, I. V.; Eggert,
U.; Niess, B.; Hoffmann, H. M. R. Tetrahedron 2003, 59, 6967.
(5) Bode, J. W.; Gauthier, D. R.; Carreira, E. M. Chem. Commun. 2001, 2560.
(6) (a) Gao, G.; Moore, D.; Xie, R.-G.; Pu, L. Org. Lett. 2002, 4, 4143. (b)
Marshall, J. A.; Bourbeau, M. P. Org. Lett. 2003, 5, 3197.
(7) Veysoglu, T.; Mitscher, L. A.; Swayze, J. K. Synthesis 1980, 807.
(8) Taber, D. F.; Amedio, J. C.; Raman K. J. Org. Chem. 1988, 53, 2984.
(9) See Supporting Information for proof of the relative stereochemical
assignment.
(10) Holson, E. B.; Roush, W. R. Org. Lett. 2002, 4, 3719.
(11) Corey, E. J.; Rucker, C. Tetrahedron Lett. 1982, 23, 719.
(12) Rodr´ıguez, A.; Nomen, M.; Spur, B. W.; Godfroid, J. J. Tetrahedron Lett.
1999, 40, 5161.
(13) Carreira, E. M.; Du Bois, J. J. Am. Chem. Soc. 1995, 117, 8106.
(14) Smith, A. B.; Wan, Z. J. Org. Chem. 2000, 65, 3738.
(15) Zhao, M.; Li, J.; Mano, E.; Song, Z.; Tschaen, D. M.; Grabowski, E. J.
J.; Reider, P. J. J. Org. Chem. 1999, 64, 2564.
(16) Phillips, A. J.; Uto, Y.; Wipf, P.; Reno, M. J.; Williams, D. R. Org. Lett.
2000, 2, 1165.
(17) Zhang, H. X.; Guibe´, F.; Balavoine, G. J. Org. Chem. 1990, 55, 1857.
(18) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. Bull. Chem.
Soc. Jpn. 1979, 52, 1989.
(19) The synthetic material was identical in all regards (1H NMR, 13C NMR,
HRMS, [R]D) to the reported spectral data of the natural product.
Unfortunately, authentic disorazole C1 decomposed and is no longer
available for direct comparison.4a
In conclusion, the highly convergent and stereoselective synthesis
of the myxobacterium metabolite (-)-disorazole C1 was ac-
JA0443068
9
J. AM. CHEM. SOC. VOL. 126, NO. 47, 2004 15347